Jasper Therapeutics filings document a clinical-stage biotechnology issuer developing briquilimab for mast cell driven diseases. Recent Form 8-K reports furnish quarterly and year-end financial results, corporate updates, briquilimab clinical data in chronic spontaneous urticaria and related extension studies, asthma study disclosures, and executive leadership changes.
The filings also identify Nasdaq-listed voting common stock under JSPR and redeemable warrants under JSPRW, and include material-event disclosures involving capital structure, material agreements, shareholder voting matters and corporate reorganization actions tied to the company's operating plan.
Jasper Therapeutics, Inc. (Nasdaq: JSPR) filed a Form 8-K dated July 7, 2025 to disclose a material corporate event under Item 8.01.
The company issued a press release (Exhibit 99.1) announcing updated data from its BEACON Phase 1b/2a study evaluating subcutaneous briquilimab in adults with chronic spontaneous urticaria. Jasper will host a conference call and webinar on July 7, 2025 at 8:30 a.m. EDT to discuss the new findings and provide a program update. A supporting investor presentation is furnished as Exhibit 99.2. No financial statements or earnings figures accompany this filing.
Key administrative details include the trading symbols JSPR (common stock) and JSPRW (warrants), and confirmation of listing on The Nasdaq Stock Market LLC. The filing contains customary signatures and an iXBRL cover page file (Exhibit 104).